Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals

Rhea-AI Summary

Nanox (Nasdaq: NNOX) announced that its deep‑learning subsidiary Nanox.AI had two bone‑analysis tools — HealthVCF and the upgraded HealthOST — recommended by NICE for inclusion in an Early Value Assessment in UK NHS hospitals for a three‑year evidence‑generation period beginning November 24, 2025.

The tools will be assessed for their ability to support opportunistic detection of vertebral fragility fractures on X‑rays and CT scans, be compared with current NHS standard of care, and are eligible for core NHS funding while evidence is gathered. Two of five AI bone solutions in the assessment are from Nanox.AI.

Positive

• NICE inclusion for HealthVCF and HealthOST in Early Value Assessment
• Three‑year NHS use period for evidence generation
• Eligibility for core NHS funding during assessment
• Two of five AI bone solutions in assessment are from Nanox.AI

Negative

• Evidence generation required before routine adoption
• Comparative assessment against NHS standard of care may limit immediate scaling
• Assessment duration up to three years delays full evaluation outcome

Insights

Health technology strategist

NICE inclusion for a three-year Early Value Assessment gives Nanox.AI validated NHS access to generate real‑world evidence for spine AI tools.

Nanox.AI’s HealthVCF and the evolved HealthOST received recommendation into a NICE Early Value Assessment program for use in NHS hospitals for a three-year period starting Nov. 24, 2025, allowing routine deployment while evidence on detection of vertebral fragility fractures is gathered. This mechanism lets the NHS fund and compare these AI tools against current standard of care, creating an operational pathway to collect outcome and workflow data at scale.

The main dependency is evidence generation: continued clinical performance and demonstrable impact on detection and downstream care will determine long‑term adoption. Risks include failing to show incremental benefit over standard care during the assessment window and operational hurdles integrating AI into radiology workflows. Watch for interim evaluation results, uptake metrics across participating NHS sites, and any NICE follow-up decisions within the three-year assessment period.

Nanox’s HealthOST and HeathVCF recommended for use in UK National Health Service hospitals for a three-year period as the use of AI solutions in bone disease is evaluated

PETACH TIKVA, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company today announced that its deep-learning medical imaging analytics subsidiary, Nanox.AI Ltd (“Nanox. AI”, secured the recommendation of the National Institute for Health and Care Excellence (NICE), the UK’s clinical standards and reimbursement body. NICE has included both Nanox AI bone solutions in an Early Value Assessment at National Health Service (NHS) hospitals in the UK.

NICE has included Nanox AI’s HealthVCF and HealthOST, along with three other AI solutions, for evaluation in NHS hospitals to provide evidence of how AI can help support the detection of vertebral fragility fractures (VFFs), while further data on their benefits is gathered and assessed. HealthOST is the evolution of HealthVCF, which was evaluated in the AI-enabled Detection of OsteoPorosis (ADOPT) study.

“AI technologies can help healthcare professionals spot VFFs on X-ray images and CT scans involving the spine, that are done for unrelated conditions (opportunistic detection),” NICE stated in its Health Technology Evaluation. “This could help identify more people with a vertebral fragility fracture who need treatment to improve their quality of life and reduce the risk of future fractures.”

Kassim Javaid, Professor of Osteoporosis and Adult Rare Bone Disease, University of Oxford, said: “Nanox.AI’s bone solutions represent a major step forward in transforming how we detect vertebral fragility fractures and intervene earlier in osteoporosis. The ADOPT trial has shown the impact of proactive identification, and these AI tools can help bring that approach into routine NHS care. With Oxford securing an additional three years to use the HealthOST solution, we are further strengthening our ability to deliver earlier, data-driven insights. I’m delighted that NICE has recognized the potential of these tools through the Early Value Assessment, enabling us to generate the evidence needed to bring earlier detection to many more patients.”

Erez Meltzer, CEO and Acting Chairman of Nanox, commented: “Inclusion in this Early Value Assessment by NICE provides clear initial validation of the benefit that our AI bone solutions can provide in detection of vertebral fragility fractures, something which many solutions providers have yet to demonstrate. Our inclusion reflects that Nanox.AI delivers clinically validated, real-world results, not just theoretical concepts, and it’s very encouraging that two of the five bone solutions recommended by NICE are from Nanox AI, enabling us to build a footprint in UK hospitals. We look forward to working with the NHS to demonstrate how HealthVCF and HealthOST can support better detection and diagnosis of bone diseases.”

The tools may be used for a period of three years as part of evidence generation and are eligible for core NHS funding. They will be used in line with the NICE guidelines on assessing the risk of fragility fracture in osteoporosis and will be compared with current NHS standard of care in diagnosis.

About Nanox.AI Bone Solutions
HealthOST and HealthVCF analyze existing CT scans—often performed for unrelated clinical reasons. These algorithms transform routine imaging into a powerful opportunity to support early detection. This approach requires no additional imaging, introduces no extra radiation exposure and imposes no added burden on the patient, positioning Nanox AI bone solutions as a highly cost-effective method to help identify risk earlier.

Fully integrated with existing PACS workflows, HealthOST enables clinicians to uncover clinically significant findings in real time, while ensuring that patients at risk receive timely, preventive intervention. Hip fractures are closely linked to chronic pain, reduced mobility, long-term disability, and loss of independence. By detecting low bone mineral density early—before symptoms appear—Nanox.AI solutions can be truly life-changing for patients who might otherwise remain undiagnosed.

About Nanox.AI
Nanox.AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox.AI solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI, Nanox.AI helps clinicians extract valuable and actionable clinical insights from medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. For more information, please visit www.nanox.vision/ai.

About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary digital X-ray source.

Nanox's vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI to enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment and maintaining a clinically driven approach. The Nanox ecosystem includes Nanox.ARC – a multi-source digital tomosynthesis system that is cost-effective and user-friendly; Nanox.AI LTD – an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases; Nanox.CLOUD – a cloud-based software platform that manages and stores data collected by Nanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE – a proprietary decentralized marketplace through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance better health outcomes worldwide. For more information, please visit www.nanox.vision

Forward-Looking Statements

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xii) potential litigation associated with our transactions.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.

Contacts

Media Contact:
Ben Shannon, Jessica Hodgson
ICR Healthcare
NanoxPR@icrinc.com

Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com

FAQ

What did Nanox (NNOX) announce on November 24, 2025 about HealthVCF and HealthOST?

Nanox said NICE recommended HealthVCF and HealthOST for a three‑year Early Value Assessment in NHS hospitals to gather evidence on vertebral fragility fracture detection.

How long can NHS hospitals use Nanox.AI HealthOST under the NICE Early Value Assessment?

The tools may be used for up to three years as part of the evidence generation and assessment period.

Will Nanox.AI solutions receive NHS funding during the NICE assessment for NNOX?

Yes; the tools are described as eligible for core NHS funding while evidence is gathered.

What clinical purpose will HealthVCF and HealthOST serve in the NHS assessment for NNOX?

They will be evaluated for opportunistic detection of vertebral fragility fractures on X‑rays and CT scans and compared with current NHS standard of care.

How many AI bone solutions did NICE include in the Early Value Assessment and how many are from Nanox.AI?

NICE included five AI bone solutions in the assessment, with two provided by Nanox.AI.

Does the NICE recommendation mean immediate widespread NHS adoption for NNOX products?

No; the recommendation authorizes a time‑limited assessment to generate evidence before wider routine adoption is determined.